Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA doubling time (DT,< 6 months). They then asked whether such a benefit also exits in men with a protracted PSA [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
The great news for for our brothers in Europe is that Xtandi (Enzalutamide) has been approved for use in the European Union (EU) for the treatment of men with metastatic castration-resistant prostate cancer whose disease has progressed on or after chemotherapy (docetaxel). Following the regulatory review process by the European Medicines Agency (EMA) and a [...]
Infections are among the scariest possibility whenever we go into the hospital, especially for any type of surgery. The good news is that since 2008 the national rates of certain hospital infections have declined significantly. We cancer survivors are more vulnerable to infection since many of our treatments including chemotherapy temporarily suppress our immune systems. [...]
Start A Cure Update -What Went Wrong: Eliminating Mistakes in Diagnosis and Treatment of Prostate Cancer Malecare’s Start A Cure web site has begun to function in earnest. We at Malecare have become concerned about the increasing loss of funding for prostate cancer research, so we have started a “crowd funding” project to let individuals [...]